Vasoconstrictors and the cardiac patient: what is in the cartridge, what the labels warn about, and where the 0.04 mg 'cardiac dose' actually comes from

What it says#

This entry reports what the manufacturers' labels and the ADA's own topic page say. The treating dentist decides how much vasoconstrictor a particular patient can take, and a published maximum is not a target.

What is actually in the cartridge. The dental labels are inconsistent about how they express the vasoconstrictor, so the numbers below are copied exactly as printed. ARTICADENT lists "epinephrine 1:100,000 (as epinephrine bitartrate 0.018 mg/mL)" and "epinephrine 1:200,000 (as epinephrine bitartrate 0.009 mg/mL)" in 1.7 mL cartridges, so a cartridge holds 0.018 times 1.7, or 0.031 mg of epinephrine bitartrate at 1:100,000, and 0.015 mg at 1:200,000. Marcaine 0.5% with epinephrine 1:200,000 states "Each 1 mL contains 5 mg bupivacaine hydrochloride and 0.0091 mg epinephrine bitartrate," which over a 1.8 mL cartridge is 0.016 mg. Citanest Forte DENTAL at the same 1:200,000 dilution prints "Epinephrine (as bitartrate) 0.005" mg/mL, which over 1.8 mL is 0.009 mg. Polocaine DENTAL 2% with levonordefrin 1:20,000 prints "Levonordefrin 0.05 mg" per mL, which over a 1.7 mL cartridge is 0.085 mg.

Two of those figures deserve a flag. The same 1:200,000 dilution appears as 0.005 mg/mL on the prilocaine label and as 0.009 or 0.0091 mg/mL on the articaine and bupivacaine labels, because one is stating the epinephrine base and the others are stating the bitartrate salt. And the 2% Xylocaine DENTAL composition table gives only the dilution, 1:50,000 or 1:100,000, with no mg/mL figure for epinephrine at all, so this entry does not publish a per-cartridge epinephrine number for lidocaine.

The only vasoconstrictor maximum on a dental label. ARTICADENT, and the identically worded Orabloc label, are the only ones read here that cap the vasoconstrictor: "The maximum recommended dosage of ARTICADENT is 7 mg/kg of articaine and 0.0017 mg/kg of epinephrine," for healthy adults and for pediatric patients ages 4 to 16 alike. For a 70 kg adult that is 0.0017 times 70, or 0.119 mg of epinephrine. No other dental cartridge label read for this entry states any milligram ceiling for epinephrine or for levonordefrin.

Where the 0.04 mg "cardiac dose" comes from. It is not in the FDA labeling. The source that states it and was read for this entry is the American Dental Association's Hypertension oral health topic page, last updated November 1, 2022, which says "a common recommendation is to limit the epinephrine dose to 0.04 mg in adults," and equates that to one cartridge of anesthetic containing 1:50,000 epinephrine, two cartridges of 1:100,000, or four cartridges of 1:200,000. For those statements the ADA page cites two secondary sources: Hardeman JH, Hypertension and the Dental Patient, Dent Today 2017;36(1):126-8, and Moore PA and Hersh EV, Local Anesthetics for Dentistry, chapter 7 of the ADA Dental Drug Handbook: A Quick Reference, 2019. Neither of those was obtained for this entry, so what is reported here is that the ADA states the figure and names those references. Note the size of the gap: 0.04 mg is roughly a third of the 0.119 mg that the articaine label would allow a 70 kg healthy adult.

What the labels say about cardiovascular disease. The mepivacaine labels are the most specific: the solution containing a vasoconstrictor "should be used with extreme caution for patients whose medical history and physical evaluation suggest the existence of hypertension, arteriosclerotic heart disease, cerebral vascular insufficiency, heart block, thyrotoxicosis and diabetes, etc." The lidocaine label says preparations containing a vasoconstrictor should be used with caution in areas supplied by end arteries, that patients with peripheral vascular disease and hypertensive vascular disease may exhibit an exaggerated vasoconstrictor response with ischemic injury or necrosis as a result, and that such preparations should be used with caution during or following potent general anesthetics because arrhythmias may occur. Marcaine names the anesthetic agents: chloroform, halothane, cyclopropane, trichloroethylene and related agents. Septocaine adds that articaine should be used with caution in patients with heart block.

Both the lidocaine and articaine labels reprint the same American Heart Association language, attributed to Kaplan EL, editor, Cardiovascular Disease in Dental Practice, Dallas, American Heart Association, 1986: vasoconstrictor agents should be used only when it is clear the procedure will be shortened or the analgesia rendered more profound; extreme care should be taken to avoid intravascular injection; and the minimum possible amount of vasoconstrictor should be used. That last clause is the actual rule in the FDA labeling. There is no number attached to it.

The interactions the labels name. The articaine labels give the fullest list: MAO inhibitors, nonselective beta-adrenergic antagonists, or tricyclic antidepressants "may produce severe, prolonged hypertension," and phenothiazines and butyrophenones "may reduce or reverse the pressor effect of epinephrine." The lidocaine label names MAO inhibitors, tricyclic antidepressants and phenothiazines, warns of severe prolonged hypotension or hypertension, and separately states that concurrent use with a beta-adrenergic blocking agent such as propranolol or timolol "may result in dose-dependent hypertension and bradycardia with possible heart block." The mepivacaine and bupivacaine labels name MAO inhibitors, tricyclic antidepressants and ergot-type oxytocic drugs. Cocaine is named in none of them, and not in the Adrenalin epinephrine injection label either, all of which were read for this entry.

Who it applies to#

Every patient who receives a vasoconstrictor-containing cartridge, which is most patients. It matters most for the patient with a cardiac history, the patient on a nonselective beta blocker, and the long multi-quadrant appointment where cartridge count climbs without anyone tracking it.

It does not apply to plain solutions. 3% mepivacaine and 4% prilocaine plain contain no vasoconstrictor, which is exactly why they are stocked, and the trade-off is duration and hemostasis rather than safety in the abstract.

It also does not replace a medical consult. The ADA's own sedation guidelines route ASA III and IV patients to their physician, and a cardiac patient whose status you cannot characterize is a consult, not a judgment call at the chair.

What changed#

The FDA labeling has not added a cardiac epinephrine number, and that is the substantive point. Articaine's modern label added an epinephrine maximum in mg/kg, which none of the older dental labels carry, and it is several times larger than the figure most dentists were taught. The 0.04 mg number continues to circulate as if it were a regulatory limit; it is a cautionary recommendation the ADA reports and attributes to two secondary sources.

The 1986 American Heart Association reference the labels quote has not been updated in the labeling.

Where the source is#

The link under the title opens the ADA's Hypertension oral health topic page, which is the source of the 0.04 mg figure and its cartridge equivalents, and which names its own references. Everything else comes from FDA-approved labeling read on DailyMed for this entry: ARTICADENT published March 4, 2024; Orabloc published April 23, 2019; 2% Xylocaine DENTAL published August 17, 2026; Polocaine DENTAL and Carbocaine published February 23, 2024; Citanest Forte DENTAL published March 4, 2024; Marcaine dental published November 17, 2025; Septocaine published September 6, 2007; Adrenalin epinephrine injection published July 13, 2026. The Hardeman article and the ADA Dental Drug Handbook chapter that the ADA page cites were not obtained, so the 0.04 mg figure is reported here as the ADA's statement rather than as a verified primary finding. DailyMed and the ADA topic page are both free to read.